Solid Biosciences (SLDB) Expected to Announce Quarterly Earnings on Wednesday

Solid Biosciences (NASDAQ:SLDB) is projected to post its quarterly earnings results before the market opens on Wednesday, March 12th. Analysts expect Solid Biosciences to post earnings of ($0.77) per share for the quarter.

Solid Biosciences Price Performance

NASDAQ SLDB opened at $5.31 on Wednesday. Solid Biosciences has a 12 month low of $2.88 and a 12 month high of $15.05. The company has a market capitalization of $405.25 million, a price-to-earnings ratio of -1.75 and a beta of 2.01. The company’s fifty day moving average price is $3.97 and its two-hundred day moving average price is $5.63.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 12th. Chardan Capital increased their price objective on shares of Solid Biosciences from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Truist Financial began coverage on shares of Solid Biosciences in a research note on Wednesday, January 8th. They set a “buy” rating and a $16.00 price objective on the stock. Citizens Jmp upgraded shares of Solid Biosciences to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Solid Biosciences in a research report on Friday, January 10th. Nine investment analysts have rated the stock with a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $15.40.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.